Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
February 2023
-
Media ReleaseNovartis poursuit sa croissance avec une nouvelle expansion de sa marge core et franchit des étapes importantes dans l’innovationAnnonce événementielle au sens de l’art. 53 RCExercice entier Chiffre d’affaires net en hausse de +4% (tcc1, -2% USD) et résultat opérationnel core croissant de +8% (tcc, 0% USD) Innovative…
-
Media ReleaseNovartis setzt Wachstumskurs mit weiterer Steigerung der Kerngewinnmarge fort und erreicht wichtige Innovations-meilensteineAd-hoc-Mitteilung gemäss Art. 53 KR Geschäftsjahr Der Nettoumsatz stieg um +4% (kWk1, –2% USD), wobei sich das operative Kernergebnis um +8% (kWk, 0% USD) verbesserte Innovative Medicines (IM)…
-
Media ReleaseNovartis continues to grow with further core margin expansion and achieves important innovation milestonesAd hoc announcement pursuant to Art. 53 LR Full year Net sales grew +4% (cc1, -2% USD) with core operating income growing +8% (cc, 0% USD) IM sales grew +4% (cc, -2% USD) and core operating income…
-
Featured NewsNovartis 2022 Financial Results
January 2023
-
Media ReleaseSandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilarSandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar…
-
Featured NewsNovartis provides update on Phase III STAND trial assessing crizanlizumab
-
Media ReleaseSandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolioSandoz plans to acquire worldwide product rights for Mycamine®(micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly…
-
Featured NewsWorld Economic Forum 2023 -
Featured NewsNovartis shares strategy insights and highlights key pipeline catalysts at JP Morgan Healthcare Conference 2023
-
Featured NewsZolgensma Global Managed Access Program in 2023
December 2022
-
Story Access to Healthcare
Compassionate use: Providing access to much needed treatments -
Media ReleaseNovartis presents pivotal Phase III APPLY-PNH data at ASH demonstrating investigational oral monotherapy iptacopan superiority over anti-C5Trial met both primary and most secondary endpoints, showing iptacopan provided transfusion-free hemoglobin-level increases in vast majority of adult paroxysmal nocturnal hemoglobinuria (PNH)…